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a b s t r a c t
Long chain polyunsaturated fatty acids (LCPUFA) including docosahexaenoic acid (DHA) and arachidonic
acid (ARA) are increasingly transferred from mother to fetus late in pregnancy. Infants born before this
transfer is complete are at risk for deﬁciency. This study determines the relationship between gestational
age (GA) and circulating LCPUFA levels to better understand the unique needs of premature infants born
at various GAs. Whole blood was collected within the ﬁrst 7 days of life from 60 preterm (r34 weeks
GA) and 30 term infants (Z38 weeks GA) and FA levels were analyzed. Since concurrent intravenous
lipid emulsion can skew composition data, blood LCPUFA concentrations were also measured. Levels
were compared among groups, and linear regression models were used to examine the association
between FA composition and GA. Preterm infants had signiﬁcantly lower DHA and ARA levels than term
peers, and whether assessed as concentrations or compositions, both directly correlated with GA
(po0.0001). Moreover, FA comparisons suggest that premature infants have impaired synthesis of
LCPUFAs from precursors and may require preformed DHA and ARA. This study conﬁrms that essential
FA status is strongly related to GA, and that those babies born the earliest are at the greatest risk of
LCPUFA deﬁciency.
& 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Premature birth is a leading cause of infant morbidity andmortality,
and as survival has increased, there is renewed focus on improving
both short- and long-term outcomes in this high-risk population. One
way to do this is through tailored provision of key nutrients. Long chain
polyunsaturated FAs (LCPUFAs), including arachidonic acid (ARA) and
docosahexaenoic acid (DHA), are important for normal health and
development [1,2]. Increasing evidence demonstrates that DHA sup-
plementation improves visual outcomes [3–5] and neurodevelopment
[6–9] in premature infants and may decrease morbidity from bronch-
opulmonary dysplasia [10], necrotizing enterocolitis [11–14] and reti-
nopathy of prematurity [15–17]. Although supplementation studies are
promising, the optimal amount of individual fatty acids (FAs) needed at
various gestational ages (GA) is still relatively unknown [1].
There are two important families of essential LCPUFAs, the omega-
6 FAs including ARA (20:4n-6) and its 18-carbon precursor linoleic
acid (LA, 18:2n-6), and the omega-3 FAs including eicosapentaenoic
acid (EPA, 20:5n-3), DHA (22:6n-3) and their 18-carbon precursor α-
linolenic acid (ALA, 18:3n-3). These two families have different
functions and are not interchangeable, making provision of both
essential. The developing fetus is dependent on a maternal source
during pregnancy. Most LCPUFA accumulation occurs during the third
trimester [18,19] and so, infants born before this process is complete
are at risk of deﬁciency.
Previous studies have analyzed LCPUFA status in premature
babies, most commonly as part of an intervention study [10,20–
27]. However, to our knowledge, only two studies have directly
compared blood FAs between term and preterm infants across a
range of GAs [10,20]. Both studies analyzed a composition or
weight percent of total blood FAs that could be inﬂuenced by the
simultaneous infusion of lipid emulsions commonly administered
within the ﬁrst week of life to pre-term infants. This leaves some
question regarding the exact relationship between LCPUFA status
and GA. As part of a randomized trial of the use of enteral DHA
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supplementation in premature infants, we measured baseline
blood FAs as both a percent composition and actual concentration
and investigated the relationship of LCPUFAs with GA.
2. Patients and methods
2.1. Study population
Ninety infants (60 preterm and 30 term infants) who met study
criteria were recruited from the Boekelheide NICU at Sanford
Children’s Hospital between October 2012 and March 2014.
Eligible preterm infants were less than or equal to seven days of
age at enrollment and were further stratiﬁed into two groups:
early preterm (GA of 24 0/7 to 27 6/7 weeks at birth) and late
preterm (GA 28 0/7 to 34 0/7 weeks at birth). Preterm infants were
excluded if they were considered non-viable by the medical team,
or if they had multiple, severe congenital anomalies. Term infants
(38 weeks GA or greater at birth) were excluded if they were born
to diabetic mothers or were small for GA (SGA) which was deﬁned
by a birth weight less than the 10th% for adjusted GA on a World
Health Organization (WHO) growth chart. These exclusion criteria
for reference term infants were used because of previously
reported differences in FA accretion in these groups [20,28–31].
Infants were prospectively enrolled using an adaptive enrollment
method to assure that early preterm infants were included in the
study during the same time period as more commonly admitted
late preterm and term infants. The study was approved by the
Sanford Institutional Review Board, and all mothers (who had to
be at least 18 years of age) provided written, informed consent
after all procedures had been thoroughly explained and prior to
their infant’s participation.
2.2. Clinical data
Clinical data for enrolled infants and their mothers were
collected from electronic medical records following HIPPA author-
ization. Maternal data included age, gravidity, parity, race, and
obstetric estimate of GA at delivery. Maternal diabetes status was
determined by the medical problem list and results of an oral
glucose tolerance test if completed during the pregnancy. Baseline
infant data included estimated GA at birth, sex, mode of delivery,
reported race, day of life, birth weight, height, head circumference
and growth chart percentile (Fenton Growth Curve, FGC, for
preterm infants and WHO Growth Chart for term infants).
Per the standard of care in our NICU, premature infants begin
receiving total parenteral nutrition on the ﬁrst day of life which
includes 10% soybean oil-based intravenous lipid emulsion (Intra-
lipids) titrated to a typical dose of 2–3 g/kg/d by the third day of
life. Parenteral lipid emulsion is typically continued until they
reach “full enteral feedings” (100 kcal/kg/day of breast milk or
formula). In our study population, late preterm infants reached
“full enteral feedings” at a mean (SD) of 15.1 (5.1) days, and early
preterm infants at 29.5 (7.2) days. Thus, at the time of baseline
analysis (average 6.3 days of life), all premature infants were
receiving a signiﬁcant amount of LA and ALA, but no ARA and
DHA, from parenteral lipid administration. Emulsions containing
ﬁsh oil (Omegavens) were not used in this study.
2.3. Dried blood spot (DBS) fatty acid analysis
Following enrollment, a single drop of scavenged whole blood was
collected directly to a ﬁlter paper (Ahlstrom 226, PerkinElmer, Green-
ville, SC) that was pretreated with an antioxidant cocktail (Oxystop,
OmegaQuant Analytics, LLC, Sioux Falls, SD) to protect unsaturated FAs
from oxidation. Whole blood was chosen as the sample of choice
because it is a global representation of circulating FA status (including
both plasma and blood cells) and because analyses can be conducted
on as little as a single drop. After collection, cards were stored in a re-
sealable plastic bag at 4 1C with batches delivered weekly to Omega-
Quant Analytics for analysis by capillary gas chromatography as
described previously [32]. Fatty acid levels are expressed both as a
weight percent of total blood fatty acids (composition) and as a
concentration (μg/mL blood). The latter was calculated based on the
internal standard (22:3n-3) included in the assay and on the experi-
mental determination that the average volume of dried blood con-
tained in a 4-mm punch was 9.7 μL. The mean time between sample
collection and analysis in this study was 6.8 days. The stability of FAs
collected and stored in this manner has been previously evaluated by
analyzing 5 blood samples (not from this study) weekly over a 4 week
time period. There was no sample degradation detected [33]. Speciﬁ-
cally, mean baseline and 4 week values were: ARA, 11.3% and 12.0%;
and DHA, 4.5% and 4.3%. Coefﬁcients of variation were 2.5% and 5.8%,
respectively.
2.4. Statistical analysis
For continuous variables, means and standard deviations were
calculated. Categorical variables were described using frequencies and
percents. Univariate analysis of all FAs was performed using the
Kruskal–Wallis test. Linear mixed models were used to examine the
association between FA composition and GA. The mixed model
accounts for possible correlation between twins and triplets present
in the data set. The model covariance was assessed to determine if a
mixed model was needed or if the assumption of independence could
be made. For all models, the assumption of independence was justiﬁed,
so linear regression models without a random effect were used.
Continuous dependent variables were transformed as needed to meet
model assumptions. Models were adjusted for maternal age, timing of
blood collection and relative weight, and head circumference (growth
curve percentiles) at birth. Primary outcome variables for this analysis
were DHA and ARA as both compositions and concentrations. Model
diagnostics were examined to ensure that models were not overly
inﬂuenced by outliers. Additionally, two-sensitivity analyses were
undertaken to examine the effect of inclusion criteria (preterm infants
who were SGA or whose mother had diabetes during the pregnancy)
and the day of sample collection. Results for both sensitivity analyses
produced largely similar parameter estimates and therefore are not
reported separately.
3. Results
3.1. Study population
A total of 140 preterm and 176 term infants were screened and
found to be eligible for the study. Thirty term infants and 60
preterm infants were enrolled. Of the latter, 47 were late preterm
and 13 were early preterm (Table 1). For the preterm infants, the
most common reason for not enrolling was parental refusal to
participate in the DHA intervention study. For the term infants, the
most common reasons were that the infant’s heel sticks were
already done or that the target enrollment for term infants had
already been met for that period (i.e., as noted above, the rate of
preterm infant enrollment determined the rate of term infant
enrollment using our adaptive enrollment method to ensure
enrollment of infants from each GA over a similar time period).
3.2. Blood fatty acid status
The average day of life at baseline collection was 6.3 days for the
preterm infants and 2.9 days for term infants. Of the 30 term and 60
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preterm infants enrolled, one preterm blood sample was damaged and
could not be used, and one term infant was enrolled but discharged
prior to sample collection. This left 29 term and 59 preterm partici-
pants with useable whole blood FA analyses.
When early and late preterm infants were compared with term
infants, ARA levels were 27% and 12% lower when expressed as
composition (percent of whole blood FAs) and were 27% and 15%
lower when expressed as concentrations, respectively (Table 2). A
similar pattern was found for DHA, where levels were 46% and 29%
lower when expressed as a percent, and were 48% and 31% lower
when expressed as concentrations. Therefore, whether expressed
as composition or concentration, the gradients in FA levels were
similar across the GA spectrum, with levels of both ARA and DHA
being the lowest in the early preterms, intermediate in the late
preterms and highest in the term infants. Interestingly, despite the
infusion of intravenous lipid emulsion, circulating total FA con-
centrations did not vary across the GA spectrum. For the early-
preterm, late-preterm and term infants the mean (SD) FA concen-
trations in μg/mL were 994 (420), 931 (222) and 952 (241),
respectively. This may be why compositions and concentrations
of individual FAs were similar.
These univariate trends between GA and ARA and DHA were
also seen in the multivariable models using a natural logarithm
transformation which included adjustments for maternal age, day
of blood collection, and growth percentiles for weight and head
circumference (Table 3). Indeed, DHA levels were 4.3% or 3.7%
higher (composition or concentration) and ARA levels were 2.2% or
1.6% higher (composition or concentration) for each additional
week of GA gained prior to birth. These relationships are illu-
strated in Figs. 1 and 2.
Blood levels of the precursor essential FAs, LA (C18:2n6) and
ALA (C18:3n3), varied markedly by GA (Table 2). Levels were much
higher in early and late preterm infants compared with the term
infants. LA concentrations were 188% and 95% higher, and ALA
concentrations 894% and 334% higher, respectively. Similar pat-
terns were also seen in percent composition. The elongation
product of LA (C20:2n6) was elevated in the preterm infants
compared with the term infants, but all of its desaturation/
elongation metabolites (C20:3n6, ARA, C22:4n6, and C22:5n6)
were depressed. This was observed for both percent composition
and concentration.
4. Discussion and conclusions
4.1. Discussion
In this cross sectional study comparing blood FA levels we observed
lower ARA and DHA levels in preterm compared to term infants and
demonstrated a direct correlation between these essential LCPUFAs
and GA; thus very preterm infants have the highest risk of deﬁciency.
Importantly, this was true whether expressed as a percent of total
blood FAs (composition) or concentration which were feasibly mea-
sured using a dried blood spot methodology. Comparison of all FAs
suggests that premature infants have impaired biosynthesis of LCPUFAs
from precursor FAs compared to term infants and may require
preformed provision of ARA and DHA.
Two previous studies have directly compared preterm to term
LCPUFA status. First Agostoni et al. reported reduced DHA, but not
ARA, composition in late preterm (average of 35 weeks GA) vs.
term (average of 38 weeks GA) infants who were studied at day
4 of life [20]. Infants who required intravenous lipid infusions
(which could artiﬁcially alter FA status when reported as a percent
of total blood FAs) were excluded from this study. DHA levels were
2.8% in preterm (mean 35 weeks GA) and 3.9% in term infants
(mean 38 weeks GA; po0.05) [20]. Our ﬁndings, particularly those
based on LCPUFA concentrations (which would be insensitive to
dilution by intravenous lipids), support these ﬁndings from Italy.
By design, Agostoni’s study [20] was limited to relatively healthy,
older GA participants who did not require intravenous lipid
emulsion and so conclusions about very premature infants could
not be drawn.
Martin et al. included infants born at earlier GAs and found no
difference in either ARA or DHA composition between premature
(mean 27 weeks) and term (437 weeks) infants at birth [10].
However, by one week of age, DHA composition decreased 40%
from 6.9% to 4.2% at the same time that LA levels increased from
7% to 19% of total FAs [10]. Because commercially available lipid
emulsions contain precursor LA (50% of soy based emulsion) and
ALA (9%) but do not contain preformed ARA or DHA, Martin’s
ﬁndings could simply reﬂect a dilution of circulating DHA from
other intravenously infused lipids or a decreased in vivo synthesis
due to competition from ARA precursors (LA) through the same
biosynthetic pathway.
Table 1
Infant characteristics.
Variable Category Early preterm N¼13 Late preterm N¼47 Term N¼30
Gender N (%) Male 8 (61.5) 22 (46.8) 18 (60.0)
Female 5 (38.5) 25 (53.2) 12 (40.0)
Ethnicity N (%) Non-Hispanic 12 (92.3) 42 (89.4) 28 (93.3)
Unavailable/unknown 1 (7.7) 4 (8.5) 2 (6.7)
Declined 0 (0.0) 1 (2.1) 0 (0.0)
Race N (%) Caucasian/White 10 (76.9) 43 (91.5) 28 (93.3)
Unavailable/unknown 1 (7.7) 0 (0.0) 0 (0.0)
Native American 2 (15.4) 3 (6.4) 2 (6.7)
Native Hawaiian/Paciﬁc Islander 0 (0.0) 1 (2.1) 0 (0.0)
Diabetic mother N (%) Yes 2 (15.4) 3 (6.4) 0 (0.0)
No 11 (84.6) 44 (93.6) 30 (100.0)
Type of birth N (%) Singleton 11 (84.6) 23 (48.9) 30 (100.0)
Twins 2 (15.4) 18 (38.3) 0 (0.0)
Triplets 0 (0.0) 6 (12.8) 0 (0.0)
Birth length (%) mean (SD) 34.25a (26.43) 35.83a (26.89) 60.87b (22.68)
Birth weight (%) mean (SD) 55.31a (26.70) 42.60a (22.11) 52.03b (16.66)
Maternal age mean years (SD) 27.00 (4.93) 30.60 (5.51) 26.79 (5.56)
GA range 25–28 29–33 38–40
a Percentile on Fenton Growth Curve for premature infants.
b Percentile on WHO Growth Chart for term infants.
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Our present study sheds important light on these remaining
questions by using two metrics to measure LCPUFA status: percent
composition and concentration. The former has been the tradi-
tional means of expressing FA status, but in theory, composition
may be markedly biased by artiﬁcial dilution with administration
of intravenous lipid emulsions. Conﬁrming lower LCPUFA concen-
trations (which would not be affected by the presence of infused
precursor FAs) provides strong and independent conﬁrmation that
ARA and DHA levels are indeed lower in premature infants.
Because concentrations of ARA were lower, it is also unlikely that
competition (from infused LA) for the shared synthesis pathway is
the cause of low DHA levels in premature infants.
Alternative explanations may include reasons that are unique
to premature infants including very low adipose stores, an early
catabolic energy state, increased tissue needs for rapid growth/
development or decreased function of the shared enzymatic
pathway of LCPUFA synthesis from precursor FAs. We demon-
strated that total circulating FA concentrations were not higher in
preterm compared to term infants. This suggests that premature
infants rapidly clear intravenous lipids from circulation. This is
Table 2
Blood fatty acid levels (percent composition and concentration in early and late pre-term and term infants.
Fatty acids expressed as percent of total blood fatty acids Percent
differences vs
term
Fatty acids expressed as a concentration in whole blood
(μg/mL)
Percent
differences
vs term
Fatty acid Early pre-term
(n¼13)
Late pre-term
(n¼46)
Term (n¼29) p-Value Early
(%)
Late
(%)
Early Pre-term
(n¼13)
Late pre-term
(n¼46)
Term (n¼29) p-Value Early
(%)
Late
(%)
C22:6n3
(DHA)
2.66% (0.64) 3.53% (0.54) 4.97% (1.08) o0.0001 46 29 24.99 (5.87) 32.73 (7.41) 47.66 (15.97) o0.001 48 31
C20:4n6
(ARA)
12.19% (2.21) 14.52% (1.97) 16.59% (1.69) o0.0001 27 12 115.73 (25.43) 134.41 (28.26) 158.75 (37.87) o0.001 27 15
Other fatty
acids
C14:0 0.39% (0.15) 0.56% (0.45) 0.66% (0.19) o0.0001 41 15 3.76 (1.5) 5.42 (5.84) 6.28 (2.22) o0.001 40 14
C16:0 22.2% (1.70) 23.78% (0.97) 26.2% (1.44) o0.0001 15 9 216.95 (68.52) 221.11 (42.80) 249.23 (53.08) 0.003 13 11
C16:1n7t 0.07% (0.05) 0.07% (0.04) 0.08% (0.05) 0.69 13 13 0.61 (0.29) 0.68 (0.43) 0.76 (0.39) 0.46 20 11
C16:1n7 0.43% (0.33) 0.51% (0.16) 1.25% (0.46) o0.0001 66 59 4.13 (2.76) 4.77 (2.02) 11.81 (4.75) o0.001 65 60
C18:0 13.28% (1.70) 14.44% (1.18) 15.1% (0.69) 0.0006 12 4 127.96 (32.458) 133.92 (26.12) 143.95 (30.75) 0.05 11 7
C18:1t 0.25% (0.05) 0.36% (0.18) 0.33% (0.13) 0.04 24 9 2.52 (1.06) 3.42 (1.88) 3.13 (1.28) 0.2 19 9
C18:1n9 17.88% (1.80) 16.16% (1.29) 15.83% (1.36) 0.002 13 2 182.04 (88.98) 151.06 (34.5) 150.69 (33.03) 0.42 21 0
C18:2n6t 0.35% (0.09) 0.36% (0.10) 0.38% (0.12) 0.56 8 5 3.32 (1.09) 3.37 (1.14) 3.59 (1.97) 0.56 8 6
C18:2n6 21.66% (5.16) 16.6% (3.08) 8.42% (2.72) o0.0001 157 97 229.37 (159.41) 155.65 (45.22) 79.67 (30.2) o0.001 188 95
C20:0 0.28% (0.05) 0.28% (0.04) 0.25% (0.05) 0.0004 12 12 2.68 (0.67) 2.55 (0.47) 2.29 (0.41) 0.03 17 11
C18:3n6 0.16% (0.07) 0.13% (0.04) 0.08% (0.03) o0.0001 100 63 1.61 (0.79) 1.25 (0.48) 0.8 (0.29) o0.001 101 56
C20:1n9 0.21% (0.03) 0.22% (0.06) 0.2% (0.07) 0.12 5 10 2.07 (0.84) 2.06 (0.60) 1.89 (0.71) 0.4 10 9
C18:3n3 1.07% (0.49) 0.53% (0.33) 0.13% (0.08) o0.0001 723 308 11.53 (9.63) 5.04 (3.67) 1.16 (0.80) o0.001 894 334
C20:2n6 0.39% (0.08) 0.39% (0.11) 0.23% (0.07) o0.0001 70 70 3.76 (1.11) 3.65 (1.12) 2.13 (0.68) o0.001 77 71
C22:0 0.54% (0.10) 0.51% (0.12) 0.46% (0.13) 0.02 17 11 5.11 (1.05) 4.68 (0.93) 4.18 (0.85) 0.009 22 12
C20:3n6 1.75% (0.56) 2.1% (0.44) 2.48% (0.46) o0.0001 29 15 16.57 (5.83) 19.43 (5.27) 23.54 (6.30) o0.001 30 17
C24:0 0.37% (0.10) 0.36% (0.09) 0.37% (0.07) 0.54 0 3 3.44 (0.69) 3.32 (0.89) 3.46 (0.74) 0.54 1 4
C20:5n3 0.35% (0.35) 0.33% (0.35) 0.35% (0.50) 0.45 0 6 3.1 (3.04) 2.99 (3.21) 3.23 (4.63) 0.33 4 7
C24:1n9 0.28% (0.13) 0.27% (0.08) 0.24% (0.08) 0.19 17 13 2.57 (.82) 2.52 (0.79) 2.27 (0.67) 0.4 13 11
C22:4n6 2.01% (0.42) 2.54% (0.47) 3.46% (0.52) o0.0001 42 27 18.88 (4.11) 23.33 (4.85) 33.06 (8.34) o0.001 43 29
C22:5n6 0.73% (.20) 0.96% (0.26) 1.41% (0.33) o0.0001 48 32 6.95 (2.26) 8.82 (2.50) 13.44 (3.92) o0.001 48 34
C22:5n3 0.5% (0.21) 0.47% (0.13) 0.51% (0.11) 0.25 2 8 4.68 (1.77) 4.36 (1.51) 4.89 (1.57) 0.33 4 11
Table 3
nRegression model estimates for DHA and ARA concentration and percent composition.
DHA blood concentration (μg/mL) ARA blood concentration (μg/mL)
Parameter Estimate SE p-Value Estimate SE p-Value
Gestational age 0.03591 0.00739 o .0001 0.01626 0.00621 0.0106
Mother’s age 0.00444 0.00504 0.381 0.01359 0.00424 0.0019
Weight % 0.00097 0.00172 0.5739 0.00016 0.00144 0.9123
Head circumference % 0.000282 0.00147 0.8485 3.9E-05 0.00124 0.9749
Day blood collected 0.01774 0.0146 0.228 0.00612 0.01228 0.6195
DHA composition (wt:wt%) ARA composition (wt:wt%)
Parameter Estimate SE p-Value Estimate SE p-Value
Gestational age 0.0419 0.00527 o .0001 0.02224 0.00382 o .0001
Mother’s age 0.00764 0.0036 0.037 0.00151 0.00261 0.5643
Weight % 0.00127 0.00123 0.3036 0.000459 0.000887 0.6061
Head circumference % 0.00151 0.00105 0.1544 0.00127 0.000759 0.0994
Day blood collected 0.01765 0.01043 0.0942 0.00604 0.00755 0.4261
n Parameter estimates for data with a natural logarithm transformation.
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consistent with clinical practice ﬁndings in our NICU where
intravenous lipid infusions are not routinely advanced if serum
triglyceride levels are signiﬁcantly elevated (an uncommon event).
This ﬁnding may also explain why the FA composition and
concentration data were consistently associated. The observation
that some or both of the immediate metabolic products of LA
(elongation, C20:2n6 and Δ-6 desaturation, C18:2n6 and C18:3n6)
are elevated in preterm babies, but all subsequent metabolites,
(C20:3n6 through C22:5n6) are lower suggests a “blockade” in the
production of C20:3n6 (dihomo-gamma-linolenic acid) is present
in premature infants (Fig. 3). If so, then provision of both
preformed ARA and DHA may be necessary for very premature
infants.
4.2. Strengths and limitations
Signiﬁcant strengths of this study include that it followed
adaptive enrollment methods to assure that the study included
infants in different GA groups over the same time period. The term
reference group excluded both IDM and SGA neonates who
reportedly have altered maternal-fetal LCPUFA transport. We used
whole blood, which can be seen as a surrogate for all circulating FA
fractions (plasma and cells), a validated dried blood spot method
of collection for improved study logistics, and we reported FA
status in both percent composition and concentration terms. In
doing so, we demonstrated that FA proﬁles, both percent compo-
sition and concentration, can be obtained from one drop of
scavenged blood, allowing the assessment of FA status in pre-
mature infants without additional painful procedures or blood
collection. This is beneﬁcial because neonates, especially very low
birth weight infants, have a very limited blood volume with a
higher risk of anemia, which can hinder serial blood sampling for
research. Cord blood samples are generally easier to obtain with-
out detrimental effects to the infant, but may not exclusively
represent infant status [34,35].
Weaknesses include the lack of information on maternal diet-
ary and supplementation habits. Clearly, higher maternal intake of
DHA (whether from ﬁsh or supplements) can inﬂuence newborn
blood DHA levels [36]. Also this was a single-center study that
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took place in the upper Midwest, where ﬁsh intake is typically
minimal and mother’s milk DHA levels are very low [37]. This
feature might actually be advantageous in exploring normal
LCPUFA physiology relatively independent of diet.
5. Conclusion
This study sheds light on existing questions and advances the
understanding of differences in essential FA status between pre-
term and term infants. We found that GA directly correlates with
both ARA and DHA levels in the ﬁrst week of life, so that infants
born at the lowest GA are at the highest risk of deﬁciency.
Additional ﬁndings suggest that due to impaired biosynthesis,
premature infants have the need for preformed LCPUFAs rather
than precursor essential FAs that are currently provided. Knowl-
edge gained adds to a growing platform aimed at tailoring
nutritional provision for the very premature infant with the hopes
of improving both short- and long-term outcomes.
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Summary
Long chain polyunsaturated fatty acids (LCPUFA) including
docosahexaenoic acid (DHA) and arachidonic acid (ARA) are
increasingly transferred from mother to fetus late in pregnancy
to support rapid growth. Infants born before this transfer is
complete are at risk for deﬁciency. This study determines the
relationship between gestational age (GA) and LCPUFA status to
better understand the unique needs of premature infants. Whole
blood was collected within the ﬁrst week of life from 60 preterm
(o34 weeks GA) and 30 term infants (438 weeks GA). Both fatty
acid (FA) composition and concentration were analyzed and
compared, and the association between GA and LCPUFA status
was examined. Preterm infants had signiﬁcantly lower DHA and
ARA levels than term peers and levels directly correlated with GA
(po0.0001). This study conﬁrms that those babies born the
earliest are at the greatest risk of LCPUFA deﬁciency.
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